Saturday, 31 October 2026European Markets

MAISONS DU MONDE Stock Was 9.33% Up Today

Loading stream...

(vianews) - the market ended the session with maisons du monde (mdm.pa) jumping 9.33% to €4.97 on wednesday, after four consecutive sessions in a row of losses. cac 40 rose 0.24% to €7,267.64, after two successive sessions in a row of losses, on what was a somewhat positive trend trading session today.

maisons du monde's last close was €4.55, 65.97% under its 52-week high of €13.36.

about maisons du monde

maisons du monde s.a., through its subsidiaries, provides home and living room related products in france and internationally. the company's decorative products include bed linen products, carpets, candles, pillows and cushions, clocks, tableware, lamps, kitchen utensils, mirrors and frames, vases, storage units, curtains and net curtains, and bath products. it also provides furniture, such as sofas, chairs, beds, mattresses and bedframes, floor lamps, tables, and junior furniture; and tables and storage units comprising bookshelves, wardrobes, and cupboards, as well as outdoor furniture. in addition, the company offers warehouse logistics and order preparation services, as well as container transport services between harbor and warehouses. it provides its products under the maisons du monde brand. the company was founded in 1996 and is based in vertou, france.

earnings per share

as for profitability, maisons du monde has a trailing twelve months eps of €0.62.

pe ratio

maisons du monde has a trailing twelve months price to earnings ratio of 8.02. meaning, the purchaser of the share is investing €8.02 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.3%.

more news about maisons du monde (mdm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com